HomeAI · summaries
Storia in 2 fonti
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
- ·
healio.com
FDA approves self-administered furosemide injector to treat edema in heart failure, CKD
MannKind announced the FDA approved an at-home furosemide self-injection for treatment of edema in adults with HF or chronic kidney disease.The furosemide autoinjector (Furoscix…